Definitive Contract HHSN261201200036C
Award Date
9/28/12
Potential Completion Date
8/27/13
Potential Value
$170K
Federal Agency
National Cancer Institute
Awardee
Pharmaco-Kinesis Corporation
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Inglewood, CA 90304, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
<p>This is a $191,326 firm-fixed-price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lipomedics LTD, a small business limited liability company, to reformulate cancer therapeutics using nanotechnology. The contract has a ceiling value of $191,326 and an ultimate completion date of November 1, 2013. This contract is set aside for total small business participation.</p>
This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...
<p>This is a $199,386 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Sensopath Technologies, Inc., a woman-owned small business. The contract is for "TAS::75 0849::TAS TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS" and has a period of performance through July 8, 2011. The contract was set aside for small businesses.</p>
<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This is a $1,199,956.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanovector Incorporated. The contract is for "OTHER FUNCTIONS TOPIC 267, MULTIFUNCTIONAL THERAPEUTICS USING ENGINEERED PLANT VIRUS NANOPARTICLES" and was set aside for small businesses. The contract has an ultimate completion date of September 27, 2014 and was awarded on September 28, 2012. This contract appears to be part of the NCI's research and development...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Vignet Inc., a minority-owned, woman-owned small business. The contract is for the SBIR (Small Business Innovation Research) Phase II program, with the objective of developing an early detection system for melanoma using smartphones, cognitive computing, and family social support. The contract has a ceiling value of $1,266,629.47 and a period of performance ending on March 19, 2022. The...